Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nurandociguat and Nitroglycerin Interaction Study in Stable Coronary Artery Disease
NCT07431294Phase 1Not yet recruiting
- Sponsor
- Bayer
- Start
- Jan 2027
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial in chronic kidney disease (CKD) comparing Nurandociguat Arm with Placebo Arm (2 arms). Primary endpoint: Treatment-Emergent Adverse Events up to 7 weeks. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
BAY3283142
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07431294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07431294.